Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 17/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 15/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14516244 | 0.92 | PTGS1 (0.79) | PTGS1PTGS2MAPT | |
| SCHEMBL8302475 | 0.86 | PTGS1 (0.71) | PTGS1PTGS2POLBTDP1 | |
| SCHEMBL14497495 | 0.86 | PTGS1 (0.76) | PTGS1PTGS2POLB | |
| SCHEMBL14497481 | 0.86 | PTGS1 (0.74) | PTGS1PTGS2 | |
| SCHEMBL8289148 | 0.84 | PTGS1 (0.67) | PTGS1PTGS2POLBTDP1 | |
| SCHEMBL14516168 | 0.80 | PTGS1 (0.80) | PTGS1PTGS2 | |
| SCHEMBL14516618 | 0.79 | PTGS1 (0.76) | PTGS1PTGS2MAPT | |
| SCHEMBL14497482 | 0.78 | PTGS1 (0.73) | PTGS1PTGS2 | |
| SCHEMBL14497488 | 0.77 | PTGS1 (0.81) | PTGS1PTGS2 | |
| SCHEMBL14497486 | 0.76 | PTGS1 (0.63) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | PTGS2, PTGS1, PTGES2 | PTGS1 2/4885PTGS2 1/4885POLB 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.